首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Population pharmacokinetics of tacrolimus in kidney transplant patients.
【24h】

Population pharmacokinetics of tacrolimus in kidney transplant patients.

机译:他克莫司在肾脏移植患者中的群体药代动力学。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The purpose of this study was to derive population pharmacokinetics (PPK) model of tacrolimus clearance, identify and describe factors that influence it in Serbian kidney transplant patients. METHODS: Population pharmacokinetics analysis was performed using nonlinear mixed-effects model (NONMEM) program from Serbian adult kidney transplant patients receiving triple immunosuppressive therapy, including oral tacrolimus. Details of drug dosage history, sampling time and tacrolimus concentration in 63 patients (44 males and 19 females), 27 - 57 years old (age mean 40.88 +/- 7.01 years) were collected retrospectively. Effects of several covariates on tacrolimus clearance were tested: total body weight, gender, age, posttransplantation days, hemoglobin count, CRP, alanine aminotransferase/aspartate aminotransferase, total daily dose of tacrolimus, co-medication with cotrimoxasole, omeprazole, mycophenolate mofetil and prednisone (> 25 mg). RESULTS: Typical mean value of tacrolimus clearance, estimated by the base model (without covariates), in our population was 1.03 l h-1. The final model showed that tacrolimus clearance increased with total daily dose and concomitant administration of high-dose prednisone (> 25 mg). The magnitude of prednisone effect was + 1.16 l h-1. Final model was validated in a group of 17 patients, showing good predictive performance. CONCLUSIONS: The derived model describes well tacrolimus clearance in terms of characteristics of Serbian kidney transplant patients, offering basis for rational individualization of tacrolimus dosing regimens.
机译:目的:本研究的目的是推导他克莫司清除率的人群药代动力学(PPK)模型,确定并描述影响塞尔维亚肾脏移植患者的药物代谢动力学的因素。方法:使用非线性混合效应模型(NONMEM)程序对接受口服三氯苯丙胺的三联免疫抑制治疗的塞尔维亚成年肾移植患者进行人群药代动力学分析。回顾性收集了63名27岁至57岁(平均年龄40.88 +/- 7.01岁)的63名患者(男性44例,女性19例)的用药史,采样时间和他克莫司浓度的详细信息。测试了几个协变量对他克莫司清除率的影响:总体重,性别,年龄,移植后天数,血红蛋白计数,CRP,丙氨酸氨基转移酶/天冬氨酸氨基转移酶,他克莫司的日总剂量,与cotrimoxasole,奥美拉唑,霉酚酸酯和强的松酮合用(> 25毫克)。结果:基本模型估计的他克莫司清除率的平均值(无协变量)在我们的人群中为1.03 l h-1。最终模型显示他克莫司清除率随每日总剂量和高剂量泼尼松(> 25 mg)的同时给药而增加。泼尼松效应的幅度为+1.16 l h-1。最终模型在一组17名患者中得到验证,显示出良好的预测性能。结论:该衍生模型根据塞尔维亚肾脏移植患者的特点描述了良好的他克莫司清除率,为他克莫司给药方案的合理个体化提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号